|
|
|
| The Relationship between the Expression Level of Tumor Tissue and Plasma miR-146a and the Clinicopathological Features and Prognosis of Patients with Intrahepatic Cholangiocarcinoma |
| ZOU Yong, YU Changwen |
| Hanchuan People's Hospital, Hubei Hanchuan 431600, China |
|
|
|
|
Abstract Objective: To evaluate the association of circulating and tumor tissue miR-146a expressions with the clinicopathological properties and their correlations with prognosis in surgical patients with intrahepatic cholangiocarcinoma (ICC). Methods: 66 ICC patients were enrolled in the study. ICC tissues sample and plasma sample before operation were collected. The expression of miR-146a was determined by quantitative polymerase chain reaction (qPCR). Results: MiR-146a expressions in plasma were positively associated with that in tumor tissue (R=0.342, P=0.005). Tissue miR-146a was negatively correlated with poor differentiation (R=-0.253, P=0.041), TNM stage (R=-0.316, P=0.010), as well as ECOG performance (R=-0.386, P=0.001), while plasma miR-146a was inversely associated with N stage (R=-0.251, P=0.042) and TNM stage (R=-0.282, P=0.022). Kaplan-Meier curves suggested that high expression of tissue miR-146a was correlated with prolonged overall survival (OS) (P<0.001), while plasma miR-146a didn't (P=0.061). For the purpose of evaluating the prognostic value of tumor tissue or plasma miR-146a for NSCLC patients, univariate Cox regression analysis was performed, which indicated that tissue miR-146a could predict better OS (P<0.001); ECOG high performance (P=0.036), T high stage (P=0.005), N high stage (P=0.032), M high stage (P=0.006), and TNM high stage (P=0.019) could predict worse OS. Furthermore, multivariate Cox regression analysis revealed that only tissue miR-146a high expression was an independent factor for prolonged OS (P=0.001), while T high stage was a risk factor for OS. Conclusion: The expression level of miR-146a in tumor tissue and plasma is correlated with the clinicopathological characteristics of ICC patients, and miR-146a in tumor tissue may serve as a credible prognostic marker for ICC patients.
|
|
|
|
|
|
[1] Vijgen S, Terris B, Rubbia-brandt L. Pathology of intrahepatic cholangiocarcinoma[J]. Hepatobiliary Surg Nutr, 2017, 6(1): 22~34.
[2] Padia SA. Intrahepatic Cholangiocarcinoma[J]. Tech Vasc Interv Radiol, 2015, 18(4): 227~235.
[3] Li J, Tan S, Kooger R, et al. MicroRNAs as novel biological targets for detection and regulation[J]. Chem Soc Rev, 2014, 43(2): 506~517.
[4] Dong H, Lei J, Ding L, et al. MicroRNA: function, detection, and bioanalysis[J]. Chem Rev, 2013, 113(8): 6207~6233.
[5] Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders[J]. Nat Rev Mol Cell Biol, 2012, 13(4): 239~250.
[6] Hwang S, Lee YJ, Song GW, et al. Prognostic impact of tumor growth type on 7th AJCC staging system for intrahepatic cholangiocarcinoma: a single-center experience of 659 cases[J].Gastrointest Surg, 2015, 19(7): 1291~1304.
[7] Wang WM, Liu JC. Effect and molecular mechanism of mir-146a on proliferation of lung cancer cells by targeting and regulating MIF gene[J]. Asian Pac Trop Med, 2016, 9(8): 806~811.
[8] Zhou L, Zhao X, Han Y, et al. Regulation of UHRF1 by miR-146a/b modulates gastric cancer invasion and metastasis[J]. FASEB, 2013, 27(12): 4929~4939.
[9] Sun X, Zhang J, Hou Z, et al. miR-146a is directly regulated by STAT3 in human hepatocellular carcinoma cells and involved in anti-tumor immune suppression[J]. Cell Cycle,2015, 14(2): 243~252.
[10] Rong M, He R, Dang Y, et al. Expression and clinicopathological significance of miR-146a in hepatocellular carcinoma tissues[J]. Ups Med Sci, 2014, 119(1): 19~24.
[11] Zavala V, Perez-moreno E, Tapia T, et al. miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival[J]. Cancer Biomark, 2016, 16(1): 99~107. |
|
|
|
2018, Vol. 24 
